| A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma (NCT00794638) | SymBio Pharmaceuticals | 2008-11-01 |
| Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas (NCT00783367) | Abramson Cancer Center at Penn Medicine | 2008-07-01 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| Evaluation of Patient and Lesion Specific Prognostic Factors for Standard Radioimmunotherapy (NCT01151358) | University Hospital, Saarland | 2008-05-01 |
| Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma (NCT00722930) | Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas | 2008-04-01 |
| A Phase I/II Trial of VR-CHOP in Lymphoma Patients (NCT00634179) | Emory University | 2008-02-01 |
| A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma (NCT00636792) | Millennium Pharmaceuticals, Inc. | 2008-02-01 |
| Idiotypic Vaccination for Follicular Lymphoma Patients (NCT00530140) | Clinica Universidad de Navarra, Universidad de Navarra | 2007-10-01 |
| Zevalin® First Line in Follicular Lymphoma (NCT00772655) | Charite University, Berlin, Germany | 2007-10-01 |
| Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (NCT00907348) | Fondazione Italiana Linfomi - ETS | 2007-10-01 |
| Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar (NCT00475332) | University of Florida | 2007-09-01 |
| Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma (NCT01493479) | The Christie NHS Foundation Trust | 2007-06-06 |
| Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (NCT00487305) | Dana-Farber Cancer Institute | 2007-06-01 |
| Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma (NCT01446562) | Sunnybrook Health Sciences Centre | 2007-05-01 |
| A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma (NCT00479167) | Rush University Medical Center | 2007-05-01 |
| Dietary Intervention in Follicular Lymphoma (NCT00455416) | Oslo University Hospital | 2007-04-01 |
| First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (NCT00801281) | Polish Lymphoma Research Group | 2007-02-01 |
| Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE) (NCT02316613) | Hoffmann-La Roche | 2007-02-01 |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies (NCT00406809) | AbbVie (prior sponsor, Abbott) | 2006-11-01 |
| Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma (NCT00440388) | Ascenta Therapeutics | 2006-10-01 |
| Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) (NCT00384111) | Spectrum Pharmaceuticals, Inc | 2006-10-01 |
| Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma (NCT01130194) | St. Louis University | 2006-07-01 |
| Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma (NCT00774826) | Fondazione Italiana Linfomi - ETS | 2005-12-01 |
| Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (NCT00719888) | Fred Hutchinson Cancer Center | 2005-11-18 |
| Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies (NCT00275431) | Ascenta Therapeutics | 2005-11-01 |
| A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma (NCT00136591) | Lymphoma Study Association | 2005-09-01 |
| Primary Rituximab and Maintenance (NCT00140582) | Lymphoma Study Association | 2004-12-01 |
| Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) (NCT00096460) | Medical College of Wisconsin | 2004-08-01 |
| VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma (NCT00085696) | Millennium Pharmaceuticals, Inc. | 2004-05-01 |
| Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia (NCT00513175) | University of California, San Francisco | 2001-10-01 |
| Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia (NCT00022971) | National Cancer Institute (NCI) | 2001-08-15 |
| Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma (NCT00169208) | Lymphoma Study Association | 2001-04-01 |
| Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon (NCT03069248) | Sunnybrook Health Sciences Centre | 2000-06-01 |
| Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma (NCT00435955) | Azienda Ospedaliera San Giovanni Battista | 2000-03-01 |
| Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab (NCT00393107) | Gruppo Italiano Studio Linfomi | 2000-03-01 |
| Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma (NCT00115700) | Trans Tasman Radiation Oncology Group | 2000-02-01 |
| Vaccination of Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype (NCT00001572) | National Cancer Institute (NCI) | 1997-01-30 |
| Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines (NCT00001512) | National Cancer Institute (NCI) | 1996-09-09 |
| Randomized Study for Patients With Follicular Lymphoma Needing Treatment (NCT00140569) | Lymphoma Study Association | 1994-01-01 |
| Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy (NCT00859001) | University of Bologna | |
| Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel (NCT05776160) | Kite, A Gilead Company | |